Your browser doesn't support javascript.
loading
Radiation Therapy Technology Advances and Mitigation of Subsequent Neoplasms in Childhood Cancer Survivors.
Stokkevåg, Camilla H; Journy, Neige; Vogelius, Ivan R; Howell, Rebecca M; Hodgson, David; Bentzen, Søren M.
Affiliation
  • Stokkevåg CH; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway; Department of Physics and Technology, University of Bergen, Bergen, Norway. Electronic address: camilla.stokkevag@uib.no.
  • Journy N; French National Institute of Health and Medical Research (INSERM) Unit 1018, Centre for Research in Epidemiology and Population Health, Paris Saclay University, Gustave Roussy, Villejuif, France.
  • Vogelius IR; Department of Clinical Oncology, Centre for Cancer and Organ Diseases and University of Copenhagen, Copenhagen, Denmark.
  • Howell RM; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
  • Hodgson D; Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
  • Bentzen SM; Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland.
Int J Radiat Oncol Biol Phys ; 119(2): 681-696, 2024 Jun 01.
Article in En | MEDLINE | ID: mdl-38430101
ABSTRACT

PURPOSE:

In this Pediatric Normal Tissue Effects in the Clinic (PENTEC) vision paper, challenges and opportunities in the assessment of subsequent neoplasms (SNs) from radiation therapy (RT) are presented and discussed in the context of technology advancement. METHODS AND MATERIALS The paper discusses the current knowledge of SN risks associated with historic, contemporary, and future RT technologies. Opportunities for research and SN mitigation strategies in pediatric patients with cancer are reviewed.

RESULTS:

Present experience with radiation carcinogenesis is from populations exposed during widely different scenarios. Knowledge gaps exist within clinical cohorts and follow-up; dose-response and volume effects; dose-rate and fractionation effects; radiation quality and proton/particle therapy; age considerations; susceptibility of specific tissues; and risks related to genetic predisposition. The biological mechanisms associated with local and patient-level risks are largely unknown.

CONCLUSIONS:

Future cancer care is expected to involve several available RT technologies, necessitating evidence and strategies to assess the performance of competing treatments. It is essential to maximize the utilization of existing follow-up while planning for prospective data collection, including standardized registration of individual treatment information with linkage across patient databases.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organs at Risk / Cancer Survivors / Neoplasms, Radiation-Induced Limits: Adolescent / Child / Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2024 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organs at Risk / Cancer Survivors / Neoplasms, Radiation-Induced Limits: Adolescent / Child / Humans Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2024 Document type: Article Country of publication: United States